Kamada Ltd (KMDA) stock
Close on Nov 11, 2026Market cap $468.99MP/E –Yield –
Kamada Ltd grew revenue 13.2% to $191.85M over the twelve months to Jun 30, 2026. Operating income rose 10.3% to $27.83M, moving the operating margin from 14.9% to 14.5%. At the latest close the market valued the company at $468.99M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $468.99M
- P/E ratio
- –
- Price to sales
- 2.44
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $191.85M
- EPS, diluted
- $0.35
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $8.10
- Open
- $8.07
- Day's range
- $8.03 – $8.15
- Volume
- 120,825
- Average volume (20 days)
- 111,985
- Beta (5 years)
- 0.76
- 52-week range
- $6.59 – $9.35
- RSI (14 days)
- 56.2
- Volatility (1 year)
- 36.6%
- Relative volume
- 1.08×
- WACC
- 8.7%
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | KMDA | S&P 500 | Difference | KMDA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +0.6% | -2.4% | +3.0 pts | ||
| 3 months | +17.0% | -1.2% | +18.2 pts | ||
| Year to date | +21.1% | +12.3% | +8.8 pts | ||
| 1 year | +21.1% | +12.4% | +8.7 pts | ||
| 3 years | +87.9% | +78.8% | +9.1 pts | +23.4% | +21.4% |
| 5 years | +55.7% | +75.2% | −19.5 pts | +9.3% | +11.9% |
| 10 years | +62.9% | +311.1% | −248.2 pts | +5.0% | +15.2% |
Twelve years at a glance
Fiscal years 2014 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Press releases
Releases Kamada filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Kamada
Pharmaceutical Preparations
Kamada Ltd. is a biopharmaceutical company focused on the development, manufacturing, and commercialization of plasma-derived protein therapeutics. The company conducts business primarily through two distinct segments: Proprietary Products and Distribution. Its portfolio of commercial proprietary therapeutics includes KEDRAB for rabies exposure, GLASSIA for alpha-1 antitrypsin deficiency, CYTOGAM for cytomegalovirus, along with WINRHO SDF, HEPAGAM B, and VARIZIG. Through its distribution operations, the company markets third-party pharmaceuticals and biosimilar products. Its customer base includes healthcare systems, medical facilities, hospitals, physicians, and commercial partners worldwide.
Company profile, executives and historyKamada stock: common questions
What is Kamada's stock price?
KMDA closed at $8.13 on Nov 11, 2026, up 0.37% on the day. Over the past 52 weeks it traded between $6.59 and $9.35.
What is Kamada's market cap?
Kamada was worth $468.99M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
How much revenue does Kamada make?
Kamada reported revenue of $191.85M for the twelve months to Jun 30, 2026, up 13.2% from a year earlier.
Does Kamada pay a dividend?
No. Kamada has not paid a cash dividend over the last twelve months.
When does Kamada report earnings next?
Kamada's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has KMDA stock performed over the past year?
Including dividends, KMDA returned +21.1% over the past year, against +12.4% for the S&P 500.
How many KMDA shares are sold short?
0M shares were sold short at the latest FINRA report, 0.53% of the float, or 2.6 days of average trading volume.
Who are Kamada's competitors?
Companies most similar to Kamada by business, industry and size include INCR, AKBA, LGND, RIGL, CYRX.
See a number that looks wrong?